Champions Oncology Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Champions Oncology's estimated annual revenue is currently $20.2M per year.
- Champions Oncology received $5.2M in venture funding in June 2016.
- Champions Oncology's estimated revenue per employee is $167,281
- Champions Oncology's total funding is $36.8M.
- Champions Oncology has 121 Employees.
- Champions Oncology grew their employee count by 14% last year.
- Champions Oncology currently has 21 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Champions Oncology?
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Champions Oncology News
Ronnie Morris has been the CEO of Champions Oncology, Inc. (NASDAQ:CSBR) since 2017. This report will, first, examine the CEO ...
The Price to Book ratio for Champions Oncology, Inc. NasdaqCM:CSBR is 31.618851. The Price to book ratio is the current share price of a ...
Champions Oncology Inc (NASDAQ:CSBR)'s share price passed below its 200-day moving average during trading on Thursday . The stock ...
Champions Oncology Funding
|2015-03-13||$14.0M||Undisclosed||New Enterprise Associates||Article|
|2016-06-13||$5.2M||Undisclosed||National Securities Corporation||Article|
Champions Oncology Executive Hires
|2011-11-02||Gary G. Gemignani||EVP/CFO||Article|
|2014-01-07||Angela Davies||Chief Medical Officer||Article|
|2014-03-05||Ido Ben-Zvi||Dir Bioinformatics/Machine Learning||Article|
|2018-05-02||Amy Wesa||Dir Immuno-Oncology Research||Article|
Champions Oncology New Location/Offices